Uncategorized

Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech’s $83M

Published

4 hours ago

on

A blood test might predict who will respond to Wegovy; Viridian’s thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets.

🧬 Second life for a gene therapy: A Cleveland-based biotech called …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version